Skip to content
Skip to content

NextGenAMR — a product by Vanguard Biotech Systems

The NextGenAMR pilot process

A pilot is a controlled institutional evaluation — initially retrospective and non-interventional — run in parallel to your laboratory's usual workflow, to study whether NextGenAMR fits technically and operationally. Submitting this form starts a fit review; it is not a commitment.

NextGenAMR is a functional platform in controlled preview. Validation is ongoing, and the product is not presented as an autonomous diagnostic or treatment-decision system.

What a pilot studies

Technical and operational fit, data processability, run traceability, report completeness and utility, reproducibility, the frequency and causes of abstention or failure, processing time, professional-review time, and fit to your local workflow. Pilot results do not replace your reference method and are not used autonomously to diagnose, report susceptibility, select treatment or change care decisions.

How the evaluation works

A real sequence of work. No data or files are requested until a controlled environment is prepared and approved.

  1. 01Initial discoveryNo data or files requested
    What happens
    VBS and the institution identify the objective, the laboratory, the current workflow, the scientific scope, the people involved, general constraints and the question you want to answer.
    Who takes part
    Laboratory / innovation lead and VBS.
    What is decided
    Whether there is enough mutual interest to move to a fit review.
  2. 02Fit reviewNo data or files requested
    What happens
    Organism, panel, input, approximate volume, reference method, product maturity, institutional requirements and general compatibility are checked against the published scope.
    Who takes part
    Microbiology / bioinformatics and VBS.
    What is decided
    Advance, request additional non-sensitive information, or conclude that the product does not currently fit.
  3. 03Data & requirements evaluationNo data or files requested
    What happens
    The nature of the dataset is characterised: provenance, format, expected quality, governance, sensitivity, volume, transfer mechanism and conditions of use. No dataset is sent through the form or by ordinary email.
    Who takes part
    Data governance / privacy, laboratory and VBS.
    What is decided
    Whether a suitable, legitimately usable dataset can be defined — prioritising retrospective de-identified data.
  4. 04Protocol definitionNo data or files requested
    What happens
    Objective, population or dataset, inclusion/exclusion criteria, reference standard, endpoints, repetitions, failure handling, abstention handling, discordances, analysis, reporting and decision criteria are agreed before any execution.
    Who takes part
    Scientific + technical leads and VBS.
    What is decided
    A written, agreed protocol with success criteria fixed in advance.
  5. 05Controlled deployment preparationNo data or files requested
    What happens
    Architecture, access, responsibilities, secure transfer, retention, deletion, support, versioning, traceability, readiness and the conditions to start are confirmed. Not every institution follows exactly the same deployment.
    Who takes part
    IT / security / privacy, laboratory and VBS.
    What is decided
    Readiness sign-off: data reception and processing do not begin until the applicable conditions are met.
  6. 06ExecutionApproved dataset processed
    What happens
    The approved dataset is processed; versions and provenance are preserved; incidents are documented; the defined criteria are applied; the protocol is never silently changed to favour results.
    Who takes part
    Laboratory and VBS, under the agreed protocol.
    What is decided
    A documented set of runs with preserved versions, provenance and incidents.
  7. 07AnalysisNo data or files requested
    What happens
    Favourable and unfavourable runs, failures, exclusions, abstentions, discordances, limitations and operational observations are all included. No cherry-picking; denominators are not changed without documented justification.
    Who takes part
    Scientific + technical leads and VBS.
    What is decided
    An honest, complete analysis against the pre-agreed criteria.
  8. 08DecisionNo data or files requested
    What happens
    The institution and VBS may advance, advance with conditions, expand or repeat the evaluation, study a later integration, pause the work, or conclude that there is no current fit.
    Who takes part
    Institution leadership and VBS.
    What is decided
    A joint, non-obligatory decision — the journey is not designed to force every inquiry into contracting.

What a protocol can measure

These are evaluation objectives — dimensions a protocol may measure — not benefits already demonstrated. Success thresholds are agreed per protocol before execution, and abstentions, failures and exclusions are never hidden.

  • Data eligibility & processability

    How much of the dataset meets the input and scope conditions.

  • Completed runs

    Runs that finish and produce the expected output.

  • Technical failures & causes

    Runs that fail technically, with their causes.

  • Abstentions & causes

    Cases where the system abstains, and why.

  • Repeatability & consistency

    Consistency of results across repetitions.

  • Per-stage & total runtime

    Bioinformatic processing time — a technical measure, not a clinical turnaround or an operational saving.

  • Report completeness & provenance

    Whether the report and its provenance are complete and available.

  • Professional-review time

    Time a professional needs to review an output.

  • Discordances vs the reference

    Where applicable, differences against the reference standard.

  • Fit to the local workflow

    How well the process fits the laboratory's routine.

No clinical performance metrics (sensitivity, specificity, categorical agreement, VME/ME, accuracy) have been published. Performance evaluation is in progress.

Who contributes what

VBS provides

  • The platform in a controlled managed-cloud environment.
  • Configuration of the agreed scope.
  • Technical onboarding and data-preparation documentation.
  • Support during the evaluation.
  • Version registry and run provenance.
  • Failure investigation and result generation.
  • An aggregate closing report.

The institution provides

  • Scientific and technical leads.
  • Compatible, legitimately usable data (agreed separately, never via the form).
  • A reference method, where applicable.Scope-dependent
  • Context on the current workflow.
  • The applicable internal approvals.
  • Participation in the kickoff, monitoring and closing reviews.

Deployment for an evaluation

Available for selected deployments

NextGenAMR can be evaluated through a VBS-operated, controlled managed-cloud environment, subject to technical, contractual, scientific, privacy and security review. The architecture, region, isolation, transfer, persistence, retention, deletion and controls are agreed before any institutional data is received.

Assessed during the fit review

  • · Certain deployment requirements can be assessed during the fit review.
  • · Dataset, secure transfer, retention and deletion are agreed per evaluation.
  • · A reference-standard comparison is defined where applicable.

Not offered as current capabilities

  • On-premise, hybrid or in-hospital installation, and single-tenant or configurable regional residency, are not currently available.
  • LIMS or direct sequencer integration, service-level guarantees, always-on support and certified deletion are not offered as current capabilities.
Security & deployment

What this evaluation does not mean

  • Submitting the form does not mean a pilot has been accepted.
  • An initial call does not mean technical approval.
  • Defining a protocol does not mean purchase or implementation.
  • Running an evaluation does not mean general validation.
  • A favourable result does not remove the scientific, legal, regulatory, technical, privacy, security, leadership or procurement approvals that may apply.

Timeframe

We do not publish a fixed duration. The timeframe is defined after reviewing the scope, the data, the approvals, the deployment, the volume and the dependencies.

Assess fit for your laboratory

Tell us about your institution and what you would like to evaluate. This qualifies fit and prepares a conversation — it requests no sensitive data.

Do not submit patient data, clinical information, sample identifiers, genomic files, sequences, or any other confidential or sensitive information through this form.

Add optional context (helps us prepare)

Reminder: do not include patient data, sample identifiers, sequences or files.